261302: A Phase 3b Continuation study of the Safety and Efficacy ofPEGylated Recombinant Factor VIII (PEG-rFVIII; BAX 855) in Prophylaxis ofBleeding in Previously Treated Patients with Severe Hemophilia A

Project: Research project

Project Details

StatusFinished
Effective start/end date7/15/158/4/19

Funding

  • Baxalta Innovations GmbH
  • Baxalta Innovations GmbH